VKA Suitable Patients | |
---|---|
Apixaban-Warfarin | |
Net Cost | USD 135,06 |
Net Life Years | 0,164 |
Net QALYs | 0,172 |
ICER | |
Cost per Life Year gained | USD 823,29 |
Cost per QALY gained | USD 786,08 |
Cost per Stroke Avoided (Ischemic and Hemorrhagic) | USD 5.422,01 |
Cost per Bleed Avoided (ICH including HS and Major Bleed) | USD 3.268,66 |